buy HOPO Chelator price purchase hopo chelating agent manufacturer FANDACHEM gadolinium chelate hopo 14-1 3,4,3-LI(1,2-HOPO) buy purchase for sale 110874-36-7
hopo 14-1 chemical structure:
Description:
3,4,3-LI(1,2-HOPO), also known as FANDACHEM Gadolinium chelator HOPO 14-1 or FANDACHEM hopo chelator is a powerful heavy metal chelating agent for removal of toxic heavy metals such as Padolinium, etc.
FANDACHEM Gadolinium chelator HOPO 14-1 is an octadentate chelator that stabilizes chelation of radiolabels (e.g., 89Zr) for targeted PET imaging that is an alternative to DFO.
The complex with 89Zr exhibits equal or superior stability compared to DFO in chem. and biol. assays across a period of several days in vivo.
Synonyms: 3,4,3-(LI-1,2-HOPO);hopo 14-1;fandachem hopo;hopo fandachem;hopo chelating agent;hopo chelating agent and decorporation agent FandaChem,hopo chelate gadolinium,gadolinium hopo chelator;gadolinium chelator hopo;gadolinium chelating agent hopo;Hydroxypyridinone 1,2-hopo;LiHOPO;buy 3 4 3-LI(1 2-HOPO) cas 110874-36-7,3 4 3-LI(1 2-HOPO) purchase,3 4 3-LI(1 2-HOPO) for sale,3 4 3-LI(1 2-HOPO) manufacturer FANDACHEM;hopo chelation remove gadolinium,buy hopo chelator,hopo chelator price,hopo chelator manufacturer,gadolinium chelator hopo,gadolinium chelating agent,How to chelate gadolinium with hopo chelator from FandaChem,3,4,3-LIHOPO manufacturer FandaChem cas 110874-36-7，
Purity: ≥93%; ≥95%
Appearance: solid powder
CAS No.: 110874-36-7
MF: C34H38N8O12
MW: 750.71
Package: 5g; 10g; 20g;100g
Manufacturer and supplier: FANDACHEM
Contact FANDACHEM:
E-mail: [email protected]
Whatsapp: 0086 158-5814-5714
Shipping terms: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping.
Storage Condition: Dry, dark and at 0 - 4 C for short term (at least 2 months) or -20 C for long term (2 years at least).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
HS code: 29349990
Use:
Gadolinium chelating agent ( Gadolinium Chelator HOPO 14-1 from FANDACHEM),
hopo chelator for Radioactive elements like plutonium,americium,other actinides,
hopo chelator for Gadolinium-based contrast agents caused toxicity,
hopo chelator (removal of gadolinium-based contrast),
hopo chelator for Zirconium-89
References:
Pallares RM, Carter KP, Zeltmann SE, Tratnjek T, Minor AM, Abergel RJ. Selective Lanthanide Sensing with Gold Nanoparticles and Hydroxypyridinone Chelators. Inorg Chem. 2020 Feb 3;59(3):2030-2036. doi: 10.1021/acs.inorgchem.9b03393. Epub 2020 Jan 23. PubMed PMID: 31971379.
Younes A, Creff G, Beccia MR, Moisy P, Roques J, Aupiais J, Hennig C, Solari PL, Den Auwer C, Vidaud C. Is hydroxypyridonate 3,4,3-LI(1,2-HOPO) a good competitor of fetuin for uranyl metabolism? Metallomics. 2019 Feb 20;11(2):496-507. doi: 10.1039/c8mt00272j. PubMed PMID: 30644488.
Sadhu B, Mishra V. The coordination chemistry of lanthanide and actinide metal ions with hydroxypyridinone-based decorporation agents: orbital and density based analyses. Dalton Trans. 2018 Nov 27;47(46):16603-16615. doi: 10.1039/c8dt03262a. PubMed PMID: 30417921.
Carter KP, Jian J, Pyrch MM, Forbes TZ, Eaton TM, Abergel RJ, de Jong WA, Gibson JK. Reductive activation of neptunyl and plutonyl oxo species with a hydroxypyridinone chelating ligand. Chem Commun (Camb). 2018 Sep 20;54(76):10698-10701. doi: 10.1039/c8cc05626a. PubMed PMID: 30187044.
Chen S, Ko R, Lai EPC, Wyatt H, Abergel RJ, Li C. ENCAPSULATED 3,4,3-LI(1,2-HOPO) IN CHITOSAN NANOPARTICLES FOR DECORPORATION VIA INHALATION. Radiat Prot Dosimetry. 2018 Dec 1;182(1):107-111. doi: 10.1093/rpd/ncy139. PubMed PMID: 30165556.
Tazrart A, Bolzinger MA, Lamart S, Coudert S, Angulo JF, Jandard V, Briançon S, Griffiths NM. Actinide-contaminated Skin: Comparing Decontamination Efficacy of Water, Cleansing Gels, and DTPA Gels. Health Phys. 2018 Jul;115(1):12-20. doi: 10.1097/HP.0000000000000814. PubMed PMID: 29787426.
Kelley MP, Deblonde GJ, Su J, Booth CH, Abergel RJ, Batista ER, Yang P. Bond Covalency and Oxidation State of Actinide Ions Complexed with Therapeutic Chelating Agent 3,4,3-LI(1,2-HOPO). Inorg Chem. 2018 May 7;57(9):5352-5363. doi: 10.1021/acs.inorgchem.8b00345. Epub 2018 Apr 6. PubMed PMID: 29624372.
Rees JA, Deblonde GJ, An DD, Ansoborlo C, Gauny SS, Abergel RJ. Evaluating the potential of chelation therapy to prevent and treat gadolinium deposition from MRI contrast agents. Sci Rep. 2018 Mar 13;8(1):4419. doi: 10.1038/s41598-018-22511-6. PubMed PMID: 29535330; PubMed Central PMCID: PMC5849765.
An DD, Kullgren B, Jarvis EE, Abergel RJ. From early prophylaxis to delayed treatment: Establishing the plutonium decorporation activity window of hydroxypyridinonate chelating agents. Chem Biol Interact. 2017 Apr 1;267:80-88. doi: 10.1016/j.cbi.2016.03.034. Epub 2016 Mar 31. PubMed PMID: 27038878; PubMed Central PMCID: PMC5045775.
Deri MA, Ponnala S, Kozlowski P, Burton-Pye BP, Cicek HT, Hu C, Lewis JS, Francesconi LC. p-SCN-Bn-HOPO: A Superior Bifunctional Chelator for (89)Zr ImmunoPET. Bioconjug Chem. 2015 Dec 16;26(12):2579-91. doi: 10.1021/acs.bioconjchem.5b00572. Epub 2015 Nov 25. PubMed PMID: 26550847; PubMed Central PMCID: PMC4962612.
www.sri.com/press/story/sris-radioactive-contamination-treatment-is-now-in-its-first-in-human-trial
MAY 15, 2023 SRI’s radioactive contamination treatment is now in its first-in-human trial
(HOPO 14-1, active ingredient: 3,4,3-LI(1,2-HOPO), cas number: 110874-36-7
https://www.nih.gov/news-events/news-releases/first-human-trial-oral-drug-remove-radioactive-contamination-begins
Monday, May 15, 2023
First-in-human trial of oral drug to remove radioactive contamination begins
NIH-funded clinical trial will determine safety, tolerability of experimental drug. (HOPO 14-1, active ingredient: 3,4,3-LI(1,2-HOPO), cas number: 110874-36-7
https://classic.clinicaltrials.gov/ct2/show/NCT05628961
Study of Single Oral Doses of HOPO 14-1 Evaluating Safety, Tolerability, Pharmacokinetics
https://en.wikipedia.org/wiki/HOPO_14-1
(HOPO 14-1, active ingredient: 3,4,3-LI(1,2-HOPO), cas number: 110874-36-7
